摘要
以43例冠心病患为观察组,45名健康人为对照组,研究噻氯匹定对冠心病患者血小板聚集功能的影响.①治疗前,观察组的血小板聚集率(PAR)非常显著地高于对照组(P<0.001),且观察组中不同病变类型等亚组的PAR,在某些亚组间存在差异;②治疗后,观察组的PAR非常显著地低于治疗前(P<O.001),与对照组比较无显著性差异(P>0.06);③治疗后,观察组显效者31例(71.l%),改善者10例(23.3%),总有效率为95.4%.结果显示,噻氟匹定具有良好的抗血小板聚集作用,对冠心病的近期疗效较好.
Platelet aggregation rate(PAR) in 43 patients (M 19,F 24; Aged 39 -81a, 62±7a) with coronary heart disease was measured before and after treatment with ticlopidine. And 45 healthy individuais were for control. The practical training found that the PAR of observe group before taking ticlopidine increased obviously more over than that of control group (P<0. 001). In observe group the PAR of patients with acute myocardial infraction and unstable angina pectoreis increased obviously (P<0. 01-0. 001). The PAR of patients with heart failure inceased slightly over that of patients with no heart failure (P<0. 05). The PAR was not affected obviously in the cases whether with arrhythmia or Without arrhythmia. Observe group were treated with ticlepidine 250mg, tid, po, 3d and 250mg, qd, po. 12d, all 15d as a course of therapy. After 15d PAR of observe group decreased markedly less than that before using ticlopidine (P<0. 01). And PAR of observe group was mot obviously yet different from that of control group (P>0. 05). PAR of patients with acute myocardial infraction and unstable angina pectoris already decreased less than PAR of stable angina pectoris, and the PAR decreasement if closely associated with the improvement in clinical symptoms. The result pointed out that ticolpidine has a nature in inhibiting platelet aggregation, the higher the PAR increment, the greater the decreased range after treatment, and the better the clinical effect. Therefore ticlopidine is specially suitable for patients who have serious symptoms in coronary heart disease, and has no serious adverse effects, so it is worthwhile for clinical use.
出处
《药物流行病学杂志》
CAS
1995年第1期7-9,共3页
Chinese Journal of Pharmacoepidemiology
